Showing results (111-120 of 190) with videos related to
Sort By:
Pageof 19
JCO Precision Oncology|August 17, 2022
Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid CarcinomaJennifer Rui Wang, Matthew Montierth, Li Xu, et al.Lung Cancer (Amsterdam, Netherlands)|November 13, 2022
Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trialYufei Liu, Luyang Yao, Neda Kalhor, et al.Advances in Therapy|July 9, 2021
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II TrialRenata Ferrarotto, Luana G Sousa, Yun Qing, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2020
Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLCOlsi Gjyshi, Ting Xu, Adnan Elhammali, et al.Injury Epidemiology|June 28, 2019
Protocol for serious fall injury adjudication in the Strategies to Reduce Injuries and Develop Confidence in Elders (STRIDE) studyDavid A Ganz, Albert L Siu, Jay Magaziner, et al.JAMA Oncology|July 21, 2017
Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 StudyJoe Y Chang, Vivek Verma, Ming Li, et al.Clinical Lung Cancer|January 16, 2026
Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab UseUtsav Joshi, Faustine Ong, Daniel Melzer, et al.Nature Communications|August 10, 2016
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancersChristopher A Miller, Yevgeniy Gindin, Charles Lu, et al.Head & Neck|February 1, 2021
Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neckSamantha Tam, Mona Gajera, Xiaoning Luo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesotheliomaHedy L Kindler, Theodore G Karrison, David R Gandara, et al.Pageof 19